Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To investigate whether growth, invasion and metastasis of endometrial cancer cells is associated with neovascularization, the expressions of fibroblast growth factor-1 (acidic FGF), -2 (basic FGF) and -4 (hst-1) mRNAs and FGF-2 in endometrial cancers and normal endometria as controls were determined by reverse transcription-polymerase chain reaction-Southern blot and ELISA, respectively, and the relationships between their expressions and histological grades, grades of myometrial invasion or clinical stages of endometrial cancers were analyzed. The levels of FGF-1 mRNA and FGF-2 and its mRNA tended to increase with dedifferentiation (especially grade G3), myometrial invasion (especially grade C) and staging (especially stages III and IV) in endometrial cancers were significantly (p < 0.05) higher than those in normal endometria. However, the levels of FGF-4 mRNA expression were significantly (p < 0.05) lower than those of FGF-1 and -2 mRNAs in both endometrial cancers and normal endometria. Therefore, endometrial cancers might mainly secrete FGF-1 and -2, which leads to neovascularization to provide nutrition, resulting in accelerated growth, invasion and metastasis. Apparently, the increased secretion parallels the progressive malignancy of endometrial cancers.
 ...
PMID:Expressions of the fibroblast growth factor family (FGF-1, -2 and -4) mRNA in endometrial cancers. 868 3

To clarify the effect of sex steroids on neovascularization in the growth, invasion and metastasis of endometrial cancer, the regulations of acid fibroblast growth factor (FGF-1), basic FGF (FGF-2) and hst-1 (FGF-4) mRNA expressions were studied in well-differentiated endometrial cancer cells under the influence of sex steroids. The levels of FGF-1 and 2 mRNAs in the well-differentiated endometrial cancer (Ishikawa) cells were significantly increased by estradiol. This increase was significantly inhibited by progestins (progesterone, medroxyprogesterone acetate [MPA] and 17 alpha-hydroxyprogesterone) and tamoxifen, but not by tetrahydrocortisol, hydrocortisone and danazol. The expression of FGF-4 mRNA was not altered by sex steroids. Therefore, estrogen might stimulate FGF-2 with FGF-1 secretion of endometrial cancer cells for neovascularization, and antiestrogenic compounds do inhibit estrogen-induced events.
 ...
PMID:Antiestrogenic compounds inhibit estrogen-induced expression of fibroblast growth factor family (FGF-1, 2, and 4) mRNA in well-differentiated endometrial cancer cells. 944 20

The pituitary tumor-transforming gene (PTTG) is a novel oncogene expressed abundantly in most tumors, regulates basic fibroblast growth factor secretion, and induces angiogenesis. The objective of this study is to compare the expression rate of PTTG in endometrial cells, to correlate the level of expression of PTTG with the clinicopathologic parameters and overall survival, and to evaluate the possible use of PTTG as a prognostic marker of endometrial cancer. Forty patients diagnosed with endometrial cancer, 20 patients with endometrial hyperplasia, and 20 patients with normal endometrial tissues were included in the study. Immunohistochemical analyses on paraffin-embedded blocks were performed using a polyclonal anti-PTTG antibody. The decrease in expression of cytoplasmic and nuclear PTTG seen for endometrial cancer cells was statistically significant (P < 0.05). Cytoplasmic PTTG expression correlated with expression of progesterone receptor (P = 0.009) and FGF-2 (P = 0.007) but not with other parameters such as the expression of estrogen receptor, tumor grade, and surgical stage. Nuclear PTTG expression did not correlate with any parameters. The mean survival of patients with positive and negative cytoplasmic PTTG expression was 40.8 and 48.6 months (P = 0.78). In nuclear PTTG expression, the survival was 20.0 and 51.8 months, respectively (P = 0.04). Cytoplasmic PTTG expression was not associated with survival. Patients with nuclear PTTG overexpression showed a significant decrease in survival. The use of PTTG as a prognostic marker for endometrial cancer needs further investigation.
 ...
PMID:Expression of pituitary tumor-transforming gene in endometrial cancer as a prognostic marker. 1821 76